1st QTR PROFIT UP 9% AT SMITH & NEPHEW

10 May 1992

In the first quarter of 1992 Smith & Nephew made sales of L 201.1 million ($357.2 million), up 11% on the like, year-earlier period. The underlying increase was 8%. Pretax profit rose 9% to L 31.1 million, and earnings per share were 2.0 pence.

The results were said to reflect excellent progress in orthopedic and wound management products in the USA and in Europe. Eric Kinder, company chairman, said: "the first quarter's performance was in line with our expectations and confirms steady progress in our core health care businesses."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight